Skip to main content
38°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aerovate Therapeutics, Inc.
Aerovate Therapeutics to Explore Strategic Alternatives
July 08, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
June 17, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
May 21, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 13, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
March 27, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
March 25, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
March 06, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
November 20, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
November 13, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
August 14, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
July 11, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
June 01, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
May 22, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 15, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
March 29, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
March 02, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
January 23, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
November 17, 2022
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
November 14, 2022
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
October 18, 2022
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AVTE
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.